ECOG-4599
Regimen
- Experimental
- paclitaxel+carboplatin+bevacizumab
- Control
- paclitaxel+carboplatin
Population
Advanced non-squamous NSCLC, no brain mets, no hemoptysis
Key finding
mOS 12.3 vs 10.3 mo, HR 0.79 (0.67-0.92); first biologic on doublet in 1L non-sq NSCLC
Source: PMID 17167137
Timeline
- Enrollment start: 2002-08 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.169)